Analyst consensus rating
BridgeBio Pharma Analyst Rating: Strong Buy
Direct answer
BridgeBio Pharma's consensus rating is Strong Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $106.85.
Forecast evidence checked November 4, 2026.
Get free BridgeBio Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $74.03
- Average price target
- $106.85
- High price target
- $156.00
- Low price target
- $80.00
- Low target gap
- +8.1%
- Target upside
- +44.3%
- High target gap
- +110.7%
- Target range width
- 102.7%
- Consensus rating
- Strong Buy
- Analysts
- 20
- Evidence date
- November 4, 2026
- Valid through
- November 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BridgeBio Pharma?
BridgeBio Pharma has a verified Strong Buy consensus. The same dataset has an average price target of $106.85.
How far are BridgeBio Pharma's low and high targets from the recorded price?
The low target implies +8.1%, while the high target implies +110.7%.
How many analysts are included in BridgeBio Pharma's consensus?
The verified consensus includes 20 analysts.
How is BridgeBio Pharma's target upside or downside calculated?
The average target of $106.85 is divided by the recorded price of $74.03, then one is subtracted to produce +44.3%. This does not guarantee a future return.
When was BridgeBio Pharma's analyst forecast verified?
The data was verified on 2026-11-04. The dataset is valid through 2026-11-11.